Stockhub

Viridian Therapeutics, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

14 August 2022

31 July 2022

  • curprev 17:2017:20, 31 July 2022‎ Chris talk contribs‎ 641 bytes +641‎ Created page with "Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Viridian_Therapeutics,_Inc.’